Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Carvedilol

Preparation Calculator

Carvedilol

Non-selective Ξ² blocker + **Ξ±1** blockade

AdultBBHFHTN

Indication

HFrEF (GDMT) β€’ HTN β€’ Post-MI context β€’ Portal HTN (selected protocols)

At a glance

INDICATIONS (CORE USE)

**HTN**; **HFrEF** (evidence-based GDMT). **Orthostatic hypotension** β†’ very common early (**Ξ±1** effect) β€” **start low**, **slow titration**.

ADULT DOSE (STANDARD)

**PO:** **3.125 mg BID** HF start β†’ **double q ~2 weeks** if tolerated toward target **HTN** may start/titrate faster per label β€” still watch **standing BP**

MAX DOSE

**HF** target often **25 mg BID** (lower for weight) β€” cardiology

Route

PO

PEDIATRIC DOSE

Rare β€” specialist

Do not miss

Must-not-miss safety points

Major warning

- Orthostatic hypotension β†’ very common early (Ξ±1 effect) β€” start low, slow titration - Bradycardia - Acute decompensated HF β†’ **DO NOT start** (stabilize first); **hold** if hypotension, shock, pulmonary edema needing IV support, or escalating inotropes

Indications

USE IF: HFrEF GDMT, HTN. AVOID IF: Asthma with poor control on Ξ²-blocker, symptomatic bradycardia, **acute decompensated HF** β†’ **DO NOT start** (stabilize first).

Primary

  • Hypertension
  • HFrEF with **carvedilol** (evidence-based GDMT)

Secondary

  • Atrial fibrillation β€” **rate control**
  • Post–MI when Ξ²-blocker indicated

Other

  • **Portal hypertension** β€” selected carvedilol protocols (gastroenterology)

Dosing

STANDARD (ADULT PO)

**BID** dosing β€” take **with food** to reduce orthostasis

ADULT DOSE

**HF:** **3.125 mg BID** β†’ uptitrate slowly to **25 mg BID** (or **50 mg BID** >85 kg per label). **HTN:** start **6.25–12.5 mg BID** β†’ titrate to **BP**.

PEDIATRIC DOSE

N/A

MAX DOSE

**HF** label caps β€” verify weight band

Practical Note

**Food** with dose β€” reduces **presystemic** Ξ± effect.

Warnings

Clinical warnings

  • Ξ±1 + Ξ² blockade β†’ orthostatic hypotension (early). Reactive airway β†’ caution (Ξ²2 still relevant). HOLD if HR <50–55, SBP <90–100, symptomatic bradycardia, high-grade AV block, or acute decompensated HF with shock/hypoperfusion.
  • Ξ±1 + Ξ² blockade β†’ orthostatic hypotension (early)
  • Reactive airway disease β†’ caution (Ξ²2 still relevant)
  • Titration is often limited by hypotension before HR targets (Ξ±1 effect)

Adverse effects

  • Dizziness
  • fatigue
  • bradycardia
  • weight gain (fluid β€” HF context)

Contraindications

  • Severe hepatic impairment (label)
  • Cardiogenic shock
  • High-grade AV block (without pacing)
  • Bronchospasm with Ξ²-blocker contraindication

Drug interactions

  • Verapamil / diltiazem: avoid or use extreme caution (bradycardia / AV block / hypotension / shock risk)
  • Digoxin: additive AV-node suppression / AV block risk
  • Insulin / sulfonylureas: masks hypoglycemia warning
  • Other antihypertensives / vasodilators: additive hypotension (Ξ±1 + Ξ² effect)

Special populations

Pediatrics

Rare β€” specialist

Pregnancy

**Pregnancy:** risk/benefit β€” OB. **

Lactation

** excreted β€” caution.

Renal impairment

No major renal clearance β€” still monitor in CKD for hypotension.

Hepatic impairment

**Severe hepatic impairment** β€” contraindicated per label.

Elderly

**Orthostasis** β€” measure **standing BP** after starts.

Administration

**With food** β€” BID schedule.

Monitoring

  • Monitor: - Symptoms β†’ dizziness, syncope, fatigue - β€’ Standing BP early β€” Ξ±-blockade can worsen orthostasis (first days of titration) - Check standing BP early during titration (orthostasis risk)
  • Recheck: - Reassess ECG / PR interval / AV block risk with symptoms, IV use, or dose escalation - Reassess dose / volume / cause within 48–72h after change - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - Hold if:
    - HR <50–55
    - SBP <90–100
    - Symptomatic bradycardia
    - Acute decompensated HF
    - Hypoperfusion / cardiogenic shock
    - Pulmonary edema requiring IV therapy

    Also hold:
    - High-grade AV block
    - Severe orthostasis

Overdose / toxicity

Clinical Picture

A) Mild β†’ bradycardia, hypotension, fatigue B) Moderate β†’ sustained bradycardia + hypotension Β± AV block C) Severe β†’ shock, high-grade AV block, seizures / coma (severe toxicity)

Immediate Actions

β€’ Airway + continuous monitoring first (ABCs, telemetry, BP) β€’ Bradycardia β†’ atropine β€’ Hypotension β†’ IV fluids β€’ Early β†’ IV calcium (CaCl2 / Ca-gluconate) β€’ Glucagon 3–5 mg IV β€’ Repeat or escalate glucagon β†’ infusion if responsive (often transient) β€’ Persistent shock β†’ HIET (insulin + dextrose) β€’ Monitor glucose + potassium closely β€’ Add vasopressors if shock persists β€’ Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) β€’ Refractory severe lipophilic toxicity β†’ IV lipid emulsion (toxicology-guided) β€’ Pacing β†’ symptomatic high-grade AV block β€’ ECMO β†’ refractory shock (per center) β€’ Severe / unstable β†’ ACLS + ICU / toxicology

Antidote

- Glucagon β†’ non-Ξ² pathway (often transient) - IV calcium β†’ inotropy / conduction support - HIET β†’ metabolic rescue (refractory shock) - IV lipid β†’ lipophilic toxicity (refractory / seizures)

Decontamination

β€’ Recent **oral** ingestion β†’ **activated charcoal** if **protected airway** and within **~1–2 h** (ingestion history + risk/benefit)

Escalation

- Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) - Pacing β†’ symptomatic high-grade AV block - ECMO β†’ refractory shock (per center)

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Sit-to-stand BP** after first doses β€” **Ξ±** effect.

Clinical pearls

Portal HTN carvedilol is specialist protocol and not interchangeable with HF dosing. *Ξ²-blockers (class):* **Start low, go slow.** **HF:** only **evidence-based agents** (**metoprolol succinate**, **bisoprolol**, **carvedilol**) for **HFrEF GDMT** β€” not all Ξ²-blockers interchangeable. **Rate control (AF)** vs **BP lowering** β€” titrate to the clinical target.

Beta-blocker safety

  • Take with meals
  • HF titration schedule

Pharmacy Tool

Preparation Calculator

Carvedilol 1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Racemic; hepatic metabolism β€” food ↓ first-pass of Ξ± effect.

Mechanism of action

**Ξ²1/Ξ²2 + Ξ±1** antagonism β€” afterload reduction component.

Common brand names

Saudi Arabia

Dilatrend, Carvedilol

Global

Coreg, (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **aortic syndromes** and **thyrotoxic storm** are **protocol-driven** β€” Ξ²-blocker choice and targets are **team + guideline** specific.
  • Ξ²-blocker **GDMT for HFrEF** applies only to **evidence-based agents** β€” verify label and cardiology plan before substituting.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)

Do not miss

  • Teach **not to stop abruptly** after chronic use β€” taper when feasible
  • Titrate to **HR vs BP endpoint** (AF rate control often needs higher exposure than BP alone)
  • Take with meals
  • HF titration schedule